News
ORGS
0.160
-64.44%
-0.290
Weekly Report: what happened at ORGS last week (0601-0605)?
Weekly Report · 1d ago
Orgenesis Shareholders Approve Major Charter and Stock Increase
TipRanks · 6d ago
Weekly Report: what happened at ORGS last week (0525-0529)?
Weekly Report · 06/01 10:25
Weekly Report: what happened at ORGS last week (0518-0522)?
Weekly Report · 05/25 10:29
Weekly Report: what happened at ORGS last week (0511-0515)?
Weekly Report · 05/18 10:29
Weekly Report: what happened at ORGS last week (0504-0508)?
Weekly Report · 05/11 10:26
Weekly Report: what happened at ORGS last week (0427-0501)?
Weekly Report · 05/04 10:23
Weekly Report: what happened at ORGS last week (0420-0424)?
Weekly Report · 04/27 10:26
Weekly Report: what happened at ORGS last week (0413-0417)?
Weekly Report · 04/20 10:22
Weekly Report: what happened at ORGS last week (0406-0410)?
Weekly Report · 04/13 10:26
Weekly Report: what happened at ORGS last week (0330-0403)?
Weekly Report · 04/06 10:26
Weekly Report: what happened at ORGS last week (0323-0327)?
Weekly Report · 03/30 10:26
Weekly Report: what happened at ORGS last week (0316-0320)?
Weekly Report · 03/23 10:23
Weekly Report: what happened at ORGS last week (0309-0313)?
Weekly Report · 03/16 10:22
Orgenesis Expands Board and Appoints New Chief Financial Officer
TipRanks · 03/13 20:17
Weekly Report: what happened at ORGS last week (0302-0306)?
Weekly Report · 03/09 10:22
Weekly Report: what happened at ORGS last week (0223-0227)?
Weekly Report · 03/02 10:21
Weekly Report: what happened at ORGS last week (0216-0220)?
Weekly Report · 02/23 10:21
Weekly Report: what happened at ORGS last week (0209-0213)?
Weekly Report · 02/16 10:21
Weekly Report: what happened at ORGS last week (0202-0206)?
Weekly Report · 02/09 10:23
More
Webull provides a variety of real-time ORGS stock news. You can receive the latest news about Orgenesis Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORGS
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.